tablet contains :
Mycophenolate is indicated for the prophylaxis of organ
rejection in patients receiving allogeneic renal,
cardiac or hepatic transplants. Mycophenolate should be
used concomitantly with cyclosporine and
salvage pathway of purine synthesis in lymphocytes is
less active than the de novo synthesis of purines.
Inosine monophosphate is converted to guanosine
monophosphate by inosine monophosphate dehydrogenase.
During T-cell activation, the activity of both types I
and II inosine monophosphate dehydrogenase enzymes
increases by tenfold. Mycophenolate mofetil is converted
in the liver by ester hydrolysis to mycophenolic acid,
which in turn non-competitively and reversibly inhibits
types I and II inosine monophosphate dehydrogenase
activity during DNA synthesis in the S phase of the cell
cycle. In the salvage pathway, guanine is converted to
guanine monophosphate by the enzyme hypoxanthine-guanine
A dose of 1 g administered orally twice a day (daily
dose of 2 g) is recommended for use in renal transplant
patients or as per the physician’s advice.
MRP Retailer Stockist